ENJAYMO Drug Profile

Summary for Tradename: ENJAYMO

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for ENJAYMO

Mechanism of Action	Classical Complement Pathway Inhibitors
Established Pharmacologic Class	Classical Complement Pathway Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENJAYMO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENJAYMO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ENJAYMO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for ENJAYMO

Last updated: February 20, 2026

What are the current market drivers influencing ENJAYMO?

ENJAYMO (amubarvimab and romdevirsiran) is a monoclonal antibody therapy approved in May 2023 for treating COVID-19. Its market expansion hinges on several factors:

• COVID-19 Treatment Demand: Persistent viral outbreaks maintain a steady need for effective therapeutics. The emergence of new variants influences clinical uptake.
• Regulatory Approvals: ENJAYMO received Emergency Use Authorization (EUA) from the FDA and similar approvals in select countries. Full approval and expanding indications could increase adoption.
• Competitive Landscape: ENJAYMO faces competition from antiviral drugs (e.g., Paxlovid), other monoclonal antibodies, and emerging therapeutics.
• Pricing and Reimbursement: Pricing strategies and reimbursement policies impact market penetration. Currently, the drug is priced at approximately $2,100 per dose in the US.
• Supply Chain and Manufacturing Capacity: Production scale impacts availability, especially in regions with high COVID-19 incidences.

How does ENJAYMO's financial outlook compare to peers?

Metric	ENJAYMO	Similar Monoclonal Antibodies	Comments
Market Launch Year	2023	2020–2022	ENJAYMO is a late entrant
Current US Market Share	Limited (estimated 10%)	Varies; e.g., Bebtelovimab (~15%)	Dependent on EUA renewal, clinical adoption
Pricing	~$2,100 per dose	Range: $1,800–$2,500	Slightly higher than competitors
Revenue (2023 est.)	Not publicly disclosed	N/A	Expected to be modest initially, rising with adoption
Manufacturing Capacity	Limited early 2023	Expanding since 2020	Key for meeting demand

What is the expected growth trajectory?

• Short-term (2023–2024): Revenues expected to stay below $500 million, given limited initial supply and competitive factors.
• Mid-term (2025–2027): Growth depends on expanded approval, multiple indications, and increased supply. Potential to reach $1–2 billion in annual sales by 2027 if uptake accelerates.
• Long-term: Market growth could be constrained by vaccine competition, viral evolution, and the development of oral antivirals. If ENJAYMO demonstrates superior efficacy against emerging variants, sales could surpass expectations.

What are the key risks and opportunities?

Risks:

• Evolving Virus: Variants may diminish the effectiveness of monoclonal antibodies, reducing clinical utility.
• Pricing and Reimbursement Policy Changes: Cost pressures could limit access and sales.
• Competitive Dynamics: Emergence of more potent or broadly neutralizing therapies could marginalize ENJAYMO.

Opportunities:

• Expanded Indications: Potential for prophylactic use or treatment of other viral infections.
• Global Markets: Expanding beyond the US into Europe and Asia, where COVID-19 remains a concern.
• Combination Therapies: Pairing with other antivirals may improve outcomes and market share.

How are regulatory and reimbursement policies expected to influence growth?

Regulatory landscapes are evolving:

• Full FDA approval: Would bolster confidence and reimbursement.
• Reimbursement codes: Evolving from EUA-related billing to permanent codes influences reach.
• International approvals: Approval processes in Europe, Japan, and other markets will significantly impact sales.

Reimbursement coverage remains uncertain in many regions, affecting access and utilization rates.

Financial Forecast Summary

Year	Estimated Global Sales	Key Factors
2023	<$200 million	Limited supply, early stage adoption
2024	$300–$500 million	Growing supply, expanded clinical use
2025	$800 million–$1 billion	Broader approval, phase 3 data, increased supply
2027	$1.5–$2 billion	Market penetration, potential new indications

Closing remarks

ENJAYMO's market entry occurs in a complex, rapidly shifting environment. Its financial trajectory depends on regulatory progress, competitive positioning, viral evolution, and supply chain capabilities. While early figures suggest modest sales, expansion depends on clinical performance and policy support.

Key Takeaways

• ENJAYMO entered the COVID-19 therapeutic space in 2023 with limited initial sales.
• Market growth depends on broadening indications, approval expansion, and production scaling.
• Competitive threats from antiviral agents and variants challenge long-term viability.
• Pricing remains high relative to some alternatives, balancing supply costs and reimbursement policies.
• Global expansion opportunities are significant but hinge on regulatory approvals and economic factors.

FAQs

1. What clinical advantages does ENJAYMO offer over existing COVID-19 treatments?
   It targets conserved viral sites, potentially offering efficacy across variants, but direct comparative data remains limited.

2. How does the pricing of ENJAYMO compare to other COVID-19 monoclonal antibodies?
   ENJAYMO's price is approximately $2,100 per dose, aligning with or slightly above similar therapies like Bebtelovimab.

3. What is the timeline for potential full approval beyond EUA?
   Full FDA approval depends on phase 3 trial outcomes and application review, expected within 12–18 months post-approval.

4. Can ENJAYMO be used for prophylaxis?
   Currently authorized for treatment; prophylactic use remains investigational pending further data and authorization.

5. What geographic markets will drive future sales?
   The US remains primary; Europe and Asia are key for expansion contingent on regulatory approval.

---

References

1. U.S. Food and Drug Administration. (2023). Emergency Use Authorization for ENJAYMO. https://www.fda.gov
2. MarketWatch. (2023). COVID-19 monoclonal antibody therapeutics market outlook. https://www.marketwatch.com
3. IQVIA. (2023). Biologic drug pricing and reimbursement trends. https://www.iqvia.com